All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

FDA lifts clinical hold on the phase I/II trial of SEL24 in AML

By Anna Bartus

Share:

Jan 3, 2018


Last month, the U.S. Food and Drug Administration (FDA) lifted the clinical hold on the phase I/II clinical trial of SEL24, a first-in-class dual PIM/Fms like tyrosine kinase (FLT3) inhibitor, in patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). The aim of the study was to determine the maximum tolerated dose (MTD), safety and  anti-leukemic activity of SEL24 in R/R AML patients.

In October 2017, the AML Global Portal (AGP) reported on the clinical hold placed on the phase I/II trial of SEL24 by the FDA after the drug manufacturer’s, Selvita reported a grade 4 adverse reaction of a fatal stroke in a patient receiving the 150 mg dose of SEL24 in the dose escalation phase of the study.

The FDA agreed to lift the clinical hold on Selvita’s trial if they revise the dose-finding scheme to a standard ‘3+3 design’ under an amended protocol based on the recommendations of the FDA. Selvita says that they “will be working closely with the investigators and clinical sites to obtain IRB’s approval on the revised protocols and resume patient enrolment.”

References

More about...